Comprehensive Predictive and Pharmacodynamic Biomarker Evaluations Optimized to Preserve Precious Clinical Trial Samples
Event Date: December 7, 2021
Comprehensive biomarker profiling is crucial for executing successful precision oncology programs. Common obstacles to completing biomarker profiling studies, especially in retrospective exploratory biomarker research, are the lack of sufficient sample volume and low quality of clinical trial samples. In this presentation, Discovery Life Sciences (Discovery) will describe optimized approaches to performing genomic, proteomic, and cell-based biomarker analysis from low quantity, and in some cases low quality, clinical trial samples with a single chain of sample custody to make the most efficient use of these precious samples. Discovery’s optimized protocols and processes facilitate more comprehensive biomarker analyses from each patient than was possible in the past, with the goal of enabling faster and more accurate targeting of therapies to the right populations.